Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

A Unique Panel of Patient-Derived Cutaneous Squamous Cell Carcinoma Cell Lines Provides a Preclinical Pathway for Therapeutic Testing.

Hassan S, Purdie KJ, Wang J, Harwood CA, Proby CM, Pourreyron C, Mladkova N, Nagano A, Dhayade S, Athineos D, Caley M, Mannella V, Blyth K, Inman GJ, Leigh IM.

Int J Mol Sci. 2019 Jul 12;20(14). pii: E3428. doi: 10.3390/ijms20143428.

2.

Preclinical Evaluation of AZ12601011 and AZ12799734, Inhibitors of Transforming Growth Factor β Superfamily Type 1 Receptors.

Spender LC, Ferguson GJ, Hughes GD, Davies BR, Goldberg FW, Herrera B, Taylor RG, Strathearn LS, Sansom OJ, Barry ST, Inman GJ.

Mol Pharmacol. 2019 Feb;95(2):222-234. doi: 10.1124/mol.118.112946. Epub 2018 Nov 20.

PMID:
30459156
3.

The genomic landscape of cutaneous SCC reveals drivers and a novel azathioprine associated mutational signature.

Inman GJ, Wang J, Nagano A, Alexandrov LB, Purdie KJ, Taylor RG, Sherwood V, Thomson J, Hogan S, Spender LC, South AP, Stratton M, Chelala C, Harwood CA, Proby CM, Leigh IM.

Nat Commun. 2018 Sep 10;9(1):3667. doi: 10.1038/s41467-018-06027-1.

4.

The Role of Human Papillomaviruses and Polyomaviruses in BRAF-Inhibitor Induced Cutaneous Squamous Cell Carcinoma and Benign Squamoproliferative Lesions.

Purdie KJ, Proby CM, Rizvi H, Griffin H, Doorbar J, Sommerlad M, Feltkamp MC, der Meijden EV, Inman GJ, South AP, Leigh IM, Harwood CA.

Front Microbiol. 2018 Aug 14;9:1806. doi: 10.3389/fmicb.2018.01806. eCollection 2018.

5.

Reduced SMAD2/3 activation independently predicts increased depth of human cutaneous squamous cell carcinoma.

Rose AM, Spender LC, Stephen C, Mitchell A, Rickaby W, Bray S, Evans AT, Dayal J, Purdie KJ, Harwood CA, Proby CM, Leigh IM, Coates PJ, Inman GJ.

Oncotarget. 2018 Feb 22;9(18):14552-14566. doi: 10.18632/oncotarget.24545. eCollection 2018 Mar 6.

6.

Treating the placenta to prevent adverse effects of gestational hypoxia on fetal brain development.

Phillips TJ, Scott H, Menassa DA, Bignell AL, Sood A, Morton JS, Akagi T, Azuma K, Rogers MF, Gilmore CE, Inman GJ, Grant S, Chung Y, Aljunaidy MM, Cooke CL, Steinkraus BR, Pocklington A, Logan A, Collett GP, Kemp H, Holmans PA, Murphy MP, Fulga TA, Coney AM, Akashi M, Davidge ST, Case CP.

Sci Rep. 2017 Aug 22;7(1):9079. doi: 10.1038/s41598-017-06300-1.

7.

TGFβ pathway limits dedifferentiation following WNT and MAPK pathway activation to suppress intestinal tumourigenesis.

Cammareri P, Vincent DF, Hodder MC, Ridgway RA, Murgia C, Nobis M, Campbell AD, Varga J, Huels DJ, Subramani C, Prescott KLH, Nixon C, Hedley A, Barry ST, Greten FR, Inman GJ, Sansom OJ.

Cell Death Differ. 2017 Oct;24(10):1681-1693. doi: 10.1038/cdd.2017.92. Epub 2017 Jun 16.

8.

Targeting BRAF-mutant tumours with TGFBR1 inhibitors.

Spender LC, Inman GJ.

Aging (Albany NY). 2017 Jan 31;9(1):5-6. doi: 10.18632/aging.101169. No abstract available.

9.

TNFα drives pulmonary arterial hypertension by suppressing the BMP type-II receptor and altering NOTCH signalling.

Hurst LA, Dunmore BJ, Long L, Crosby A, Al-Lamki R, Deighton J, Southwood M, Yang X, Nikolic MZ, Herrera B, Inman GJ, Bradley JR, Rana AA, Upton PD, Morrell NW.

Nat Commun. 2017 Jan 13;8:14079. doi: 10.1038/ncomms14079.

10.

Loss of TGF-β signaling drives cSCC from skin stem cells - More evidence.

Rose AM, Sansom OJ, Inman GJ.

Cell Cycle. 2017 Mar 4;16(5):386-387. doi: 10.1080/15384101.2016.1259892. Epub 2016 Nov 18. No abstract available.

11.

Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.

Spender LC, Ferguson GJ, Liu S, Cui C, Girotti MR, Sibbet G, Higgs EB, Shuttleworth MK, Hamilton T, Lorigan P, Weller M, Vincent DF, Sansom OJ, Frame M, Dijke PT, Marais R, Inman GJ.

Oncotarget. 2016 Dec 13;7(50):81995-82012. doi: 10.18632/oncotarget.13226.

12.

Inactivation of TGFβ receptors in stem cells drives cutaneous squamous cell carcinoma.

Cammareri P, Rose AM, Vincent DF, Wang J, Nagano A, Libertini S, Ridgway RA, Athineos D, Coates PJ, McHugh A, Pourreyron C, Dayal JH, Larsson J, Weidlich S, Spender LC, Sapkota GP, Purdie KJ, Proby CM, Harwood CA, Leigh IM, Clevers H, Barker N, Karlsson S, Pritchard C, Marais R, Chelala C, South AP, Sansom OJ, Inman GJ.

Nat Commun. 2016 Aug 25;7:12493. doi: 10.1038/ncomms12493.

13.

Exosome-mediated transfer from the tumor microenvironment increases TGFβ signaling in squamous cell carcinoma.

Languino LR, Singh A, Prisco M, Inman GJ, Luginbuhl A, Curry JM, South AP.

Am J Transl Res. 2016 May 15;8(5):2432-7. eCollection 2016.

14.

The Promise of Genomics and the Development of Targeted Therapies for Cutaneous Squamous Cell Carcinoma.

Harwood CA, Proby CM, Inman GJ, Leigh IM.

Acta Derm Venereol. 2016 Jan;96(1):3-16. doi: 10.2340/00015555-2181. Review.

15.

E3 ubiquitin ligase HOIP attenuates apoptotic cell death induced by cisplatin.

MacKay C, Carroll E, Ibrahim AFM, Garg A, Inman GJ, Hay RT, Alpi AF.

Cancer Res. 2014 Apr 15;74(8):2246-2257. doi: 10.1158/0008-5472.CAN-13-2131. Epub 2014 Mar 31.

16.

Developments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signaling.

Spender LC, Inman GJ.

Cancer Manag Res. 2014 Jan 9;6:27-38. doi: 10.2147/CMAR.S37745. Review.

17.

BMP9 is a proliferative and survival factor for human hepatocellular carcinoma cells.

Herrera B, García-Álvaro M, Cruz S, Walsh P, Fernández M, Roncero C, Fabregat I, Sánchez A, Inman GJ.

PLoS One. 2013 Jul 23;8(7):e69535. doi: 10.1371/journal.pone.0069535. Print 2013.

18.

A complex secretory program orchestrated by the inflammasome controls paracrine senescence.

Acosta JC, Banito A, Wuestefeld T, Georgilis A, Janich P, Morton JP, Athineos D, Kang TW, Lasitschka F, Andrulis M, Pascual G, Morris KJ, Khan S, Jin H, Dharmalingam G, Snijders AP, Carroll T, Capper D, Pritchard C, Inman GJ, Longerich T, Sansom OJ, Benitah SA, Zender L, Gil J.

Nat Cell Biol. 2013 Aug;15(8):978-90. doi: 10.1038/ncb2784. Epub 2013 Jun 16.

19.

Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma.

Lo Nigro C, Wang H, McHugh A, Lattanzio L, Matin R, Harwood C, Syed N, Hatzimichael E, Briasoulis E, Merlano M, Evans A, Thompson A, Leigh I, Fleming C, Inman GJ, Proby C, Crook T.

J Invest Dermatol. 2013 May;133(5):1278-85. doi: 10.1038/jid.2012.493. Epub 2013 Feb 14.

20.

Exogenous heparin binds and inhibits bone morphogenetic protein 6 biological activity.

Brkljacic J, Pauk M, Erjavec I, Cipcic A, Grgurevic L, Zadro R, Inman GJ, Vukicevic S.

Int Orthop. 2013 Mar;37(3):529-41. doi: 10.1007/s00264-012-1714-3. Epub 2013 Jan 10.

Supplemental Content

Loading ...
Support Center